Okuvision

Reutlingen, GermanyFounded 200711–50 employeesokuvision.deLinkedIn

Okuvision develops and supports transcorneal electrical stimulation (TES) therapy for people with retinitis pigmentosa (RP). The company focuses on evidence-based care, clinical research, patient education, and access to its OkuStim® therapy.

Visit okuvision.de ↗

Founded: 2007
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

Okuvision’s recent public activity centers on intellectual property and continued operational support for its retinal-therapy business. On Sep 17, 2024, two patent publications were associated with the company: “Stimulation electrode assembly for a device for electrically stimulating the …” and “Device and system for electrically stimulating the eye.” The company’s intellectual-property portfolio includes 10 granted patents and nine registered trademarks, indicating sustained emphasis on electrode design, electrical eye stimulation, and brand protection. Okuvision continues to focus on OkuStim® therapy, a transcorneal electrical stimulation approach for people with retinitis pigmentosa and other degenerative retinal conditions. Its current hiring activity includes internships in quality management and regulatory affairs, as well as product development. Alfred Stett has served as Managing Director and CEO since May 2019.

Market position

Okuvision occupies a specialized position at the intersection of ophthalmology, medical devices, and therapeutics. Rather than competing broadly across ophthalmic equipment, it concentrates on transcorneal electrical stimulation for retinitis pigmentosa through the OkuStim® therapy system, including OkuStim® 2. This focus differentiates the company from general medical-device manufacturers and from pharmaceutical or gene-therapy developers pursuing retinal disease through drug or genetic interventions. Its positioning is built around a device-enabled treatment pathway, clinical research, patient education, reimbursement guidance, and engagement with ophthalmology research networks. The company’s stated evidence-based approach and CE-marked OkuStim® systems support commercialization in regulated healthcare markets, while its 10 granted patents suggest proprietary work in electrical stimulation and electrode assemblies. Okuvision appears to be a focused, specialized provider rather than a diversified medtech platform.

Growth & opportunities

Okuvision’s trajectory reflects a focused medical-device company advancing a specialized therapy rather than a high-velocity venture-growth model. Founded in 2007 and based in Reutlingen, Germany, it has developed OkuStim® Therapy around transcorneal electrical stimulation intended to slow the progression of retinitis pigmentosa. Its product scope includes the OkuStim® 2 system, while its website emphasizes clinical evidence, patient support, reimbursement information, and treatment guidance. Intellectual-property activity provides a measurable development signal: two patent publications dated Sep 17, 2024 address a stimulation electrode assembly and a device and system for electrically stimulating the eye. The company also holds 10 granted patents and nine registered trademarks. Alfred Stett has led the business as Managing Director and CEO since May 2019. Current recruitment for quality and regulatory-affairs and development internships indicates ongoing support for compliance and product engineering.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

What makes Okuvision distinct

reccy insights

What makes Okuvision distinct

01Specialized focus on transcorneal electrical stimulation for retinitis pigmentosa
02Evidence-based positioning supported by clinical studies and published research
03OkuStim® therapy has received CE marking, including for the OkuStim® 2 system
04Supports patients with treatment guidance, reimbursement information, and participation counseling
05Engages with clinical guidelines and research networks in ophthalmology

Technology & products

OkuStim Therapy
A transcorneal electrical stimulation therapy system designed to slow the progression of retinitis pigmentosa by electrically stimulating retinal cells through the eye surface.

Transcorneal electrical stimulation (TES)
OkuStim® therapy system
OkuStim® 2

About Okuvision

Products: OkuStim Therapy
Leadership: Alfred Stett, Managing Director / CEO
Focus areas: Medical devices, ophthalmology, retinitis pigmentosa, electrostimulation, medical technology, clinical research, therapeutics, healthcare
Headquarters: Reutlingen, Germany
Founded: 2007
Employees: 11–50
Patents granted: 10 (Crunchbase)
Trademarks: 9